Association of long-term administration of the survivin mRNA-targeted antisense oligonucleotide LY2181308 with reversible kidney injury in a patient with metastatic melanoma

William G. Herrington, Denis C. Talbot, Michael M. Lahn, John T. Brandt, Sophie Callies, Raymond B Nagle, Christopher G. Winearls, Ian S D Roberts

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

A 57-year-old man with metastatic melanoma was treated with the survivin inhibitor and antisense oligonucleotide LY2181308 as part of a First-in-Human Dose trial. After 18 months of treatment, he developed kidney injury and the treatment was discontinued. At 9 months and before the development of kidney injury, LY2181308 concentrations were 8- to 10-fold higher relative to median predicted values, but within the targeted exposure considered to be safe. However, at 17 months, 28 days after stopping LY2181308 therapy, LY2181308 concentration exceeded the predicted range by 38-fold. His decreased kidney function was slow to improve after stopping treatment. A kidney biopsy showed signs of acute tubular injury with regeneration. Complete recovery of kidney function occurred 6 months after treatment was stopped. The relationship between high exposures and slow LY2181308 clearance with the gradual improvement in kidney function after stopping the antisense treatment suggests that the oligonucleotide was related to the kidney injury. Based on this case report, kidney function should be monitored frequently in patients receiving long-term treatment with antisense oligonucleotides that specifically target survivin, particularly when they receive concomitant angiotensin-converting enzyme inhibitors or nonsteroidal anti-inflammatory drugs.

Original languageEnglish (US)
Pages (from-to)300-303
Number of pages4
JournalAmerican Journal of Kidney Diseases
Volume57
Issue number2
DOIs
StatePublished - Feb 2011

Fingerprint

Antisense Oligonucleotides
Melanoma
Kidney
Messenger RNA
Wounds and Injuries
Therapeutics
Recovery of Function
Angiotensin-Converting Enzyme Inhibitors
Oligonucleotides
Regeneration
Anti-Inflammatory Agents
Biopsy
Pharmaceutical Preparations

Keywords

  • Antisense oligonucleotide
  • kidney injury
  • survivin

ASJC Scopus subject areas

  • Nephrology

Cite this

Association of long-term administration of the survivin mRNA-targeted antisense oligonucleotide LY2181308 with reversible kidney injury in a patient with metastatic melanoma. / Herrington, William G.; Talbot, Denis C.; Lahn, Michael M.; Brandt, John T.; Callies, Sophie; Nagle, Raymond B; Winearls, Christopher G.; Roberts, Ian S D.

In: American Journal of Kidney Diseases, Vol. 57, No. 2, 02.2011, p. 300-303.

Research output: Contribution to journalArticle

Herrington, William G. ; Talbot, Denis C. ; Lahn, Michael M. ; Brandt, John T. ; Callies, Sophie ; Nagle, Raymond B ; Winearls, Christopher G. ; Roberts, Ian S D. / Association of long-term administration of the survivin mRNA-targeted antisense oligonucleotide LY2181308 with reversible kidney injury in a patient with metastatic melanoma. In: American Journal of Kidney Diseases. 2011 ; Vol. 57, No. 2. pp. 300-303.
@article{ce30f0bd781e403da63f83b549337124,
title = "Association of long-term administration of the survivin mRNA-targeted antisense oligonucleotide LY2181308 with reversible kidney injury in a patient with metastatic melanoma",
abstract = "A 57-year-old man with metastatic melanoma was treated with the survivin inhibitor and antisense oligonucleotide LY2181308 as part of a First-in-Human Dose trial. After 18 months of treatment, he developed kidney injury and the treatment was discontinued. At 9 months and before the development of kidney injury, LY2181308 concentrations were 8- to 10-fold higher relative to median predicted values, but within the targeted exposure considered to be safe. However, at 17 months, 28 days after stopping LY2181308 therapy, LY2181308 concentration exceeded the predicted range by 38-fold. His decreased kidney function was slow to improve after stopping treatment. A kidney biopsy showed signs of acute tubular injury with regeneration. Complete recovery of kidney function occurred 6 months after treatment was stopped. The relationship between high exposures and slow LY2181308 clearance with the gradual improvement in kidney function after stopping the antisense treatment suggests that the oligonucleotide was related to the kidney injury. Based on this case report, kidney function should be monitored frequently in patients receiving long-term treatment with antisense oligonucleotides that specifically target survivin, particularly when they receive concomitant angiotensin-converting enzyme inhibitors or nonsteroidal anti-inflammatory drugs.",
keywords = "Antisense oligonucleotide, kidney injury, survivin",
author = "Herrington, {William G.} and Talbot, {Denis C.} and Lahn, {Michael M.} and Brandt, {John T.} and Sophie Callies and Nagle, {Raymond B} and Winearls, {Christopher G.} and Roberts, {Ian S D}",
year = "2011",
month = "2",
doi = "10.1053/j.ajkd.2010.09.024",
language = "English (US)",
volume = "57",
pages = "300--303",
journal = "American Journal of Kidney Diseases",
issn = "0272-6386",
publisher = "W.B. Saunders Ltd",
number = "2",

}

TY - JOUR

T1 - Association of long-term administration of the survivin mRNA-targeted antisense oligonucleotide LY2181308 with reversible kidney injury in a patient with metastatic melanoma

AU - Herrington, William G.

AU - Talbot, Denis C.

AU - Lahn, Michael M.

AU - Brandt, John T.

AU - Callies, Sophie

AU - Nagle, Raymond B

AU - Winearls, Christopher G.

AU - Roberts, Ian S D

PY - 2011/2

Y1 - 2011/2

N2 - A 57-year-old man with metastatic melanoma was treated with the survivin inhibitor and antisense oligonucleotide LY2181308 as part of a First-in-Human Dose trial. After 18 months of treatment, he developed kidney injury and the treatment was discontinued. At 9 months and before the development of kidney injury, LY2181308 concentrations were 8- to 10-fold higher relative to median predicted values, but within the targeted exposure considered to be safe. However, at 17 months, 28 days after stopping LY2181308 therapy, LY2181308 concentration exceeded the predicted range by 38-fold. His decreased kidney function was slow to improve after stopping treatment. A kidney biopsy showed signs of acute tubular injury with regeneration. Complete recovery of kidney function occurred 6 months after treatment was stopped. The relationship between high exposures and slow LY2181308 clearance with the gradual improvement in kidney function after stopping the antisense treatment suggests that the oligonucleotide was related to the kidney injury. Based on this case report, kidney function should be monitored frequently in patients receiving long-term treatment with antisense oligonucleotides that specifically target survivin, particularly when they receive concomitant angiotensin-converting enzyme inhibitors or nonsteroidal anti-inflammatory drugs.

AB - A 57-year-old man with metastatic melanoma was treated with the survivin inhibitor and antisense oligonucleotide LY2181308 as part of a First-in-Human Dose trial. After 18 months of treatment, he developed kidney injury and the treatment was discontinued. At 9 months and before the development of kidney injury, LY2181308 concentrations were 8- to 10-fold higher relative to median predicted values, but within the targeted exposure considered to be safe. However, at 17 months, 28 days after stopping LY2181308 therapy, LY2181308 concentration exceeded the predicted range by 38-fold. His decreased kidney function was slow to improve after stopping treatment. A kidney biopsy showed signs of acute tubular injury with regeneration. Complete recovery of kidney function occurred 6 months after treatment was stopped. The relationship between high exposures and slow LY2181308 clearance with the gradual improvement in kidney function after stopping the antisense treatment suggests that the oligonucleotide was related to the kidney injury. Based on this case report, kidney function should be monitored frequently in patients receiving long-term treatment with antisense oligonucleotides that specifically target survivin, particularly when they receive concomitant angiotensin-converting enzyme inhibitors or nonsteroidal anti-inflammatory drugs.

KW - Antisense oligonucleotide

KW - kidney injury

KW - survivin

UR - http://www.scopus.com/inward/record.url?scp=78751632457&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78751632457&partnerID=8YFLogxK

U2 - 10.1053/j.ajkd.2010.09.024

DO - 10.1053/j.ajkd.2010.09.024

M3 - Article

C2 - 21177011

AN - SCOPUS:78751632457

VL - 57

SP - 300

EP - 303

JO - American Journal of Kidney Diseases

JF - American Journal of Kidney Diseases

SN - 0272-6386

IS - 2

ER -